Congenital Myasthenic Syndrome via the GFPT1 Gene
Summary and Pricing
Test Method
Sequencing and CNV Detection via NextGen Sequencing using PG-Select Capture ProbesTest Code | Test Copy Genes | Test CPT Code | Gene CPT Codes Copy CPT Code | Base Price | |
---|---|---|---|---|---|
4873 | GFPT1 | 81479 | 81479,81479 | $990 | Order Options and Pricing |
Pricing Comments
Testing run on PG-select capture probes includes CNV analysis for the gene(s) on the panel but does not permit the optional add on of exome-wide CNV analysis. Any of the NGS platforms allow reflex to other clinically relevant genes, up to whole exome or whole genome sequencing depending upon the base platform selected for the initial test.
An additional 25% charge will be applied to STAT orders. STAT orders are prioritized throughout the testing process.
This test is also offered via a custom panel (click here) on our exome or genome backbone which permits the optional add on of exome-wide CNV or genome-wide SV analysis.
Turnaround Time
3 weeks on average for standard orders or 2 weeks on average for STAT orders.
Please note: Once the testing process begins, an Estimated Report Date (ERD) range will be displayed in the portal. This is the most accurate prediction of when your report will be complete and may differ from the average TAT published on our website. About 85% of our tests will be reported within or before the ERD range. We will notify you of significant delays or holds which will impact the ERD. Learn more about turnaround times here.
Targeted Testing
For ordering sequencing of targeted known variants, go to our Targeted Variants page.
Clinical Features and Genetics
Clinical Features
Congenital myasthenic syndromes (CMS) are disorders of the neuromuscular junction resulting from defects in presynaptic, synaptic, or postsynaptic proteins. Clinically, a limb-girdle pattern of muscle involvement makes DOK7, AGRN, and GFPT1-related CMS unique from other CMS. Senderek et al. (Am J Hum Genet 88:162-172, 2011) found variants in the GFPT1 gene (OMIM 138292) in 13 families with autosomal recessive limb-girdle myasthenic syndrome with tubular aggregates (OMIM 610542). In vitro studies showed evidence for increased turnover or defective translation as an underlying pathological mechanism. Reduced numbers of acetylcholine receptors and decreased protein glycosylation were also noted (Senderek et al. 2011). Clinical symptoms, with onset during adolescence, include limb-girdle weakness and wasting with normal or slightly elevated serum CK levels (Rodolico et al. Neuromusc Disord 12:964-969, 2002). Muscle cramps and moderate exercise-induced fatigability are also documented (Sieb et al. Neuromusc Disord 6:115-119, 1996). Neither ptosis nor ophthalmoplegia are findings in GFPT1-related CMS. Electrophysiologic studies show decremental compound motor action potential responses in affected muscles, and single fiber EMG show impaired neuromuscular transmission with increased jitter (Rodolico et al. 2002). Muscle biopsies demonstrate 60-80 nm parallel subsarcolemmal tubular aggregates located predominantly in type 2 muscle fibers (Sieb et al. 1996). In contrast to DOK7-related CMS, tubular aggregates may be a universal finding in GFPT1-related CMS (Slater et al. Brain 129:2061-2076, 2006). Patients with limb-girdle myasthenic syndrome with tubular aggregates respond well to treatment with acetylcholinesterase inhibitors (Rodolico et al. 2002; Beeson et al. Science 313: 1975-1978, 2006).
Genetics
Abnormalities of proteins involved with neuromuscular transmission underlie familial limb-girdle myasthenic syndrome, congenital myasthenic syndromes, fetal akinesia deformation sequence, and multiple pterygium syndromes. These disorders, which may represent a phenotypic continuum of a single entity, are most often inherited in an autosomal recessive manner. Familial limb-girdle myasthenic syndrome with tubular aggregates due to GFPT1 variants is inherited as an autosomal recessive disorder (Senderek et al. 2011).
Clinical Sensitivity - Sequencing with CNV PG-Select
DOK7, AGRN, and GFPT1 variants are the only known cause of familial limb-girdle myasthenic syndrome. Clinical sensitivity should be high for patients meeting rigorous clinical, histopathological, and electrophysiological criteria.
Testing Strategy
This test provides full coverage of all coding exons of the GFPT1 gene, plus ~10 bases of flanking noncoding DNA. We define full coverage as >20X NGS reads or Sanger sequencing.
Indications for Test
Patients with a slowly progressive limb-girdle pattern of muscle weakness without facial involvement and tubular aggregates in muscle. Limb-girdle CMS patients who respond to AChE inhibitors. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in GFPT1.
Patients with a slowly progressive limb-girdle pattern of muscle weakness without facial involvement and tubular aggregates in muscle. Limb-girdle CMS patients who respond to AChE inhibitors. This test may also be considered for the reproductive partners of individuals who carry pathogenic variants in GFPT1.
Gene
Official Gene Symbol | OMIM ID |
---|---|
GFPT1 | 138292 |
Inheritance | Abbreviation |
---|---|
Autosomal Dominant | AD |
Autosomal Recessive | AR |
X-Linked | XL |
Mitochondrial | MT |
Disease
Name | Inheritance | OMIM ID |
---|---|---|
Familial Limb-Girdle Myasthenic Syndrome With Tubular Aggregates | AR | 610542 |
Citations
- Beeson, D., et.al. (2006). "Dok-7 mutations underlie a neuromuscular junction synaptopathy." Science 313(5795): 1975-8. PubMed ID: 16917026
- Rodolico, C., et.al. (2002). "Limb-girdle myasthenia: clinical, electrophysiological and morphological features in familial and autoimmune cases." Neuromuscul Disord 12(10): 964-9. PubMed ID: 12467753
- Senderek, J., et.al. (2011). "Hexosamine biosynthetic pathway mutations cause neuromuscular transmission defect." Am J Hum Genet 88(2): 162-72. PubMed ID: 21310273
- Sieb, J. P., et.al. (1996). "An autosomal-recessive congenital myasthenic syndrome with tubular aggregates in a Libyan family." Neuromuscul Disord 6(2): 115-9. PubMed ID: 8664562
- Slater, C. R., et.al. (2006). "Pre- and post-synaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with PubMed ID: 16870884
Ordering/Specimens
Ordering Options
We offer several options when ordering sequencing tests. For more information on these options, see our Ordering Instructions page. To view available options, click on the Order Options button within the test description.
myPrevent - Online Ordering
- The test can be added to your online orders in the Summary and Pricing section.
- Once the test has been added log in to myPrevent to fill out an online requisition form.
- PGnome sequencing panels can be ordered via the myPrevent portal only at this time.
Requisition Form
- A completed requisition form must accompany all specimens.
- Billing information along with specimen and shipping instructions are within the requisition form.
- All testing must be ordered by a qualified healthcare provider.
For Requisition Forms, visit our Forms page
If ordering a Duo or Trio test, the proband and all comparator samples are required to initiate testing. If we do not receive all required samples for the test ordered within 21 days, we will convert the order to the most effective testing strategy with the samples available. Prior authorization and/or billing in place may be impacted by a change in test code.
Specimen Types
ORDER OPTIONS
View Ordering Instructions1) Select Test Type
2) Select Additional Test Options
No Additional Test Options are available for this test.